Monographie - Ceftaroline fosamil

Ceftaroline fosamil

Molekylstruktur

Varunamn

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Zinforo

Argentina, Australien, Belgien, Brasilien, Finland, Frankrike, Irland, Island, Italien, Kroatien, Luxemburg, Malaysia, Mexiko, Norge, Rumänien, Schweiz, Slovenien, Spanien, Storbritannien, Sverige, Tunisien, Tyskland, Ungern

Hänvisningar : Ceftaroline fosamil

	Typ	Publikation
3249	tidningen	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3520	Laboratorium	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratorium	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratorium	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratorium	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3812	tidningen	Bhattacharya S, Parekh S, Dedhiya M. In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers. Int J Pharm Compound 2015 ; 19, 5 : 432-436.
3827	affisch	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	affisch	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	affisch	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	tidningen	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4059	tidningen	Madfai F, Zaidi S, Ming L, Wanandy T, Patel R. Physical and chemical stability of ceftaroline in an elastomeric infusion device. EJHP 2017 ; 25, e2
4145	tidningen	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434	tidningen	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	tidningen	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	tidningen	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4968	Laboratorium	Zinforo 600 mg powder for concentrate for solution for infusion - Summary of Product Characteristics Updated 06-Jun-2024. Pfizer Limited 2024
4971	tidningen	Coelho Mendes M, Fanfa Machioli L, Carlos G, Franco de Oliveira T, Loureiro Mendez A S. Stability of the antibiotic ceftaroline fosamil with focus on degradation products and decomposition pathways – Integrative analysis by LC-DAD, ESI-QTOF and in silico prediction J Pharm Biomed Anal 2025 ; 262: 116876.